Accordingly, any mechanism that would boost endogenous expression of decorin [71] or any therapeutic modality that could efficiently and specifically deliver decorin to carcinomas could represent a novel therapeutic choice against cancer [72], [73]. This evidence concerns the gene DCN and carcinoma.